← Back to Search

Other

MEM 3454 for Cognitive Impairment in Schizophrenia

Phase 2
Waitlist Available
Research Sponsored by Memory Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinically stable, as judged by the investigator, and in a non-acute phase for at least 12 weeks.
Diagnosis of schizophrenia (any subtype), assessed using a structured interview.
Must not have
First 3 years of schizophrenia diagnosis
Nicotine replacement therapy, smoking cessation medications or remedies, including Varenicline (Chantix)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial will test whether MEM 3454 is a safe and effective treatment for cognitive impairment associated with schizophrenia.

Who is the study for?
This trial is for adults with schizophrenia who have been stable on their current antipsychotic medication for at least one month and are not in an acute phase of illness. They must be fluent in English, able to consent, and can be smokers or non-smokers. People with other psychiatric conditions, recent hospitalization, early-stage schizophrenia, suicide risk, or substance abuse (except nicotine/caffeine) cannot join.
What is being tested?
The study tests if MEM 3454 is safe and effective when added to existing antipsychotic treatment for those with cognitive issues due to schizophrenia. Participants will either receive MEM 3454 or a placebo without knowing which one they're getting.
What are the potential side effects?
Potential side effects of MEM 3454 may include typical reactions seen with antipsychotics such as drowsiness, weight gain, dry mouth, restlessness or gastrointestinal issues; however specific side effects related to this drug will be monitored.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My condition has been stable for at least 12 weeks.
Select...
I have been diagnosed with schizophrenia.
Select...
I have been diagnosed with schizophrenia.
Select...
My health has been stable for the last 3 months.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I was diagnosed with schizophrenia within the last 3 years.
Select...
I am using nicotine replacement or smoking cessation aids.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: CExperimental Treatment1 Intervention
Group II: BExperimental Treatment1 Intervention
Group III: AExperimental Treatment1 Intervention
Group IV: DPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Memory PharmaceuticalsLead Sponsor
4 Previous Clinical Trials
335 Total Patients Enrolled

Media Library

MEM 3454 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT00604760 — Phase 2
Cognitive Impairment Research Study Groups: A, C, D, B
Cognitive Impairment Clinical Trial 2023: MEM 3454 Highlights & Side Effects. Trial Name: NCT00604760 — Phase 2
MEM 3454 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00604760 — Phase 2
Cognitive Impairment Patient Testimony for trial: Trial Name: NCT00604760 — Phase 2
~9 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top